DK3137479T3 - Oligonukleotidsammensætninger og fremgangsmåder til fremstilling af disse - Google Patents
Oligonukleotidsammensætninger og fremgangsmåder til fremstilling af disse Download PDFInfo
- Publication number
- DK3137479T3 DK3137479T3 DK15785822.6T DK15785822T DK3137479T3 DK 3137479 T3 DK3137479 T3 DK 3137479T3 DK 15785822 T DK15785822 T DK 15785822T DK 3137479 T3 DK3137479 T3 DK 3137479T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- methods
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987396P | 2014-05-01 | 2014-05-01 | |
US201562151909P | 2015-04-23 | 2015-04-23 | |
PCT/US2015/028327 WO2015168310A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods of making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3137479T3 true DK3137479T3 (da) | 2023-11-20 |
Family
ID=54359301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15785822.6T DK3137479T3 (da) | 2014-05-01 | 2015-04-29 | Oligonukleotidsammensætninger og fremgangsmåder til fremstilling af disse |
Country Status (32)
Country | Link |
---|---|
US (5) | US9796747B2 (da) |
EP (2) | EP4286519A3 (da) |
JP (6) | JP7040892B2 (da) |
KR (3) | KR20210130822A (da) |
CN (3) | CN106459134B (da) |
AP (1) | AP2016009489A0 (da) |
AU (3) | AU2015253158B2 (da) |
BR (1) | BR112016025196B1 (da) |
CA (1) | CA2943888A1 (da) |
CL (4) | CL2016002749A1 (da) |
DK (1) | DK3137479T3 (da) |
EA (1) | EA034882B9 (da) |
ES (1) | ES2963740T3 (da) |
FI (1) | FI3137479T3 (da) |
HR (1) | HRP20231505T1 (da) |
HU (1) | HUE064289T2 (da) |
IL (2) | IL248044B (da) |
JO (2) | JOP20200257A1 (da) |
LT (1) | LT3137479T (da) |
MX (2) | MX2016014178A (da) |
MY (2) | MY196927A (da) |
PE (1) | PE20170147A1 (da) |
PH (1) | PH12016502080A1 (da) |
PL (1) | PL3137479T3 (da) |
PT (1) | PT3137479T (da) |
RS (1) | RS64860B1 (da) |
SG (2) | SG11201608226YA (da) |
SI (1) | SI3137479T1 (da) |
TW (2) | TWI712413B (da) |
UA (1) | UA126108C2 (da) |
WO (1) | WO2015168310A1 (da) |
ZA (2) | ZA201606624B (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
JOP20200257A1 (ar) * | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
HUE051148T2 (hu) | 2015-04-23 | 2021-03-01 | Geron Corp | Eljárás polinukleotid elõállítására többértékû kation-só készítmények alkalmazásával |
DK3652187T3 (da) * | 2017-07-10 | 2021-12-13 | Geron Corp | Forbedret fremgangsmåde til fremstilling af imetelstat |
IL292328A (en) * | 2019-10-28 | 2022-06-01 | Geron Corp | Succinylate-converted 3-(fatty amido)-2-hydroxy-1-(hydroxy-protected)-propane salts amorphous solids and methods for their preparation |
EP4051252A4 (en) | 2019-10-28 | 2023-12-06 | Geron Corporation | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO -1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYL ETHER-PROPANE AND METHODS OF MANUFACTURE AND USE THEREOF |
EP4089099A4 (en) | 2020-01-08 | 2024-07-24 | Nitto Denko Corp | NUCLEIC ACID SYNTHESIS PROCESS USING SEGMENT AMIDITE |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
ES2055907T3 (es) | 1989-03-07 | 1994-09-01 | Genentech Inc | Conjugados covalentes de lipidos y oligonucleotidos. |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
WO1991014696A1 (en) | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US6087491A (en) | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
ATE312175T1 (de) | 1993-10-18 | 2005-12-15 | Inst Medical W & E Hall | Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
EP0754242A4 (en) | 1994-03-18 | 1997-06-11 | Lynx Therapeutics Inc | SYNTHESIS AND SUBSTANCE, HYBRIDIZATION AND NUCLEASE-RESISTANT PROPERTIES OF OLIGONUCLEOTID-N3'-m (7) P5'-PHOSPHORAMIDATE |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
DK0778842T3 (da) | 1994-07-07 | 2006-03-20 | Geron Corp | Mammal telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
AU4101396A (en) | 1994-11-07 | 1996-05-31 | Hybridon, Inc. | Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
WO1997037691A1 (en) | 1996-04-10 | 1997-10-16 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
WO1998028442A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
AU767646B2 (en) | 1999-09-10 | 2003-11-20 | Geron Corporation | Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use |
GB9927674D0 (en) * | 1999-11-23 | 2000-01-19 | Aegis Eng Ltd | Protective material |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
WO2002077184A2 (en) | 2001-03-23 | 2002-10-03 | Geron Corporation | Oligonucleotide conjugates |
US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
DK1667522T3 (da) | 2003-09-09 | 2018-03-05 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
WO2006023880A2 (en) * | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
WO2006044956A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
WO2008054711A2 (en) | 2006-10-30 | 2008-05-08 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
US20150342982A1 (en) | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
-
2014
- 2014-05-01 JO JOP/2020/0257A patent/JOP20200257A1/ar unknown
-
2015
- 2015-04-29 PE PE2016002150A patent/PE20170147A1/es unknown
- 2015-04-29 LT LTEPPCT/US2015/028327T patent/LT3137479T/lt unknown
- 2015-04-29 KR KR1020217033531A patent/KR20210130822A/ko active IP Right Grant
- 2015-04-29 US US14/699,902 patent/US9796747B2/en active Active
- 2015-04-29 RS RS20231110A patent/RS64860B1/sr unknown
- 2015-04-29 WO PCT/US2015/028327 patent/WO2015168310A1/en active Application Filing
- 2015-04-29 MX MX2016014178A patent/MX2016014178A/es unknown
- 2015-04-29 JO JOP/2015/0089A patent/JO3767B1/ar active
- 2015-04-29 AU AU2015253158A patent/AU2015253158B2/en active Active
- 2015-04-29 EA EA201691786A patent/EA034882B9/ru unknown
- 2015-04-29 CA CA2943888A patent/CA2943888A1/en active Pending
- 2015-04-29 CN CN201580022353.4A patent/CN106459134B/zh active Active
- 2015-04-29 CN CN202311295220.7A patent/CN117357548A/zh active Pending
- 2015-04-29 FI FIEP15785822.6T patent/FI3137479T3/fi active
- 2015-04-29 KR KR1020167029996A patent/KR102316282B1/ko active IP Right Grant
- 2015-04-29 PT PT157858226T patent/PT3137479T/pt unknown
- 2015-04-29 BR BR112016025196-2A patent/BR112016025196B1/pt active IP Right Grant
- 2015-04-29 HU HUE15785822A patent/HUE064289T2/hu unknown
- 2015-04-29 EP EP23193452.2A patent/EP4286519A3/en active Pending
- 2015-04-29 PL PL15785822.6T patent/PL3137479T3/pl unknown
- 2015-04-29 JP JP2016564990A patent/JP7040892B2/ja active Active
- 2015-04-29 HR HRP20231505TT patent/HRP20231505T1/hr unknown
- 2015-04-29 DK DK15785822.6T patent/DK3137479T3/da active
- 2015-04-29 KR KR1020237018801A patent/KR20230088509A/ko not_active Application Discontinuation
- 2015-04-29 EP EP15785822.6A patent/EP3137479B1/en active Active
- 2015-04-29 MY MYPI2020002421A patent/MY196927A/en unknown
- 2015-04-29 SI SI201531963T patent/SI3137479T1/sl unknown
- 2015-04-29 CN CN202010050944.5A patent/CN111228288B/zh active Active
- 2015-04-29 MY MYPI2016703971A patent/MY178617A/en unknown
- 2015-04-29 ES ES15785822T patent/ES2963740T3/es active Active
- 2015-04-29 AP AP2016009489A patent/AP2016009489A0/en unknown
- 2015-04-29 SG SG11201608226YA patent/SG11201608226YA/en unknown
- 2015-04-29 TW TW108147051A patent/TWI712413B/zh active
- 2015-04-29 SG SG10201911086XA patent/SG10201911086XA/en unknown
- 2015-04-29 UA UAA201610381A patent/UA126108C2/uk unknown
- 2015-04-29 TW TW104113709A patent/TWI709406B/zh active
-
2016
- 2016-09-23 ZA ZA2016/06624A patent/ZA201606624B/en unknown
- 2016-09-26 IL IL248044A patent/IL248044B/en active IP Right Grant
- 2016-10-19 PH PH12016502080A patent/PH12016502080A1/en unknown
- 2016-10-28 CL CL2016002749A patent/CL2016002749A1/es unknown
- 2016-10-28 MX MX2021004932A patent/MX2021004932A/es unknown
-
2017
- 2017-09-14 US US15/705,021 patent/US11299511B2/en active Active
- 2017-09-14 US US15/705,019 patent/US10392418B2/en active Active
-
2018
- 2018-05-01 JP JP2018088277A patent/JP2018131453A/ja active Pending
- 2018-05-04 CL CL2018001213A patent/CL2018001213A1/es unknown
- 2018-05-04 CL CL2018001212A patent/CL2018001212A1/es unknown
-
2019
- 2019-08-07 IL IL268570A patent/IL268570B/en unknown
- 2019-12-25 JP JP2019234301A patent/JP2020050670A/ja not_active Withdrawn
-
2020
- 2020-03-06 AU AU2020201707A patent/AU2020201707B2/en active Active
- 2020-09-22 ZA ZA2020/05857A patent/ZA202005857B/en unknown
-
2021
- 2021-09-06 JP JP2021144677A patent/JP2021182946A/ja active Pending
-
2022
- 2022-01-18 JP JP2022005584A patent/JP7308309B2/ja active Active
- 2022-01-26 CL CL2022000202A patent/CL2022000202A1/es unknown
- 2022-03-16 US US17/696,300 patent/US11739114B2/en active Active
- 2022-05-16 AU AU2022203273A patent/AU2022203273A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060170A patent/JP2023073510A/ja active Pending
- 2023-06-07 US US18/330,935 patent/US20240150391A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3782639T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
PT3325669T (pt) | Composições e métodos de análise de rna | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3149045T3 (da) | Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt | |
DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
DK3262071T3 (da) | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
DK3258962T3 (da) | Blandede allergensammensætninger og fremgangsmåde til anvendelse af disse | |
DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
DK2924093T3 (da) | Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3234110T3 (da) | FREMGANGSMÅDER TIL GENERERING AF STAMCELLE-AFLEDTE ß-CELLER OG ANVENDELSER DERAF | |
KR20180084891A (ko) | 구조 조성물 및 방법 | |
DK3484469T3 (da) | Sammensætninger og fremgangsmåder til potentiering af antimikrober | |
DK3319948T3 (da) | Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse | |
DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
DK3322695T3 (da) | Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse | |
DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf |